Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today announced that Blaine McKee, Ph.D., President and CEO will be presenting at the 41st Annual Canaccord Genuity Virtual Growth Conference.
Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. The Company believes that improving the function of podocytes – cells within the kidney that play an active role in the filtration process – represents the next frontier of renal medicine. Walden has active programs that address two novel targets for therapeutic intervention: soluble urokinase plasminogen activating receptor (suPAR) and dynamin. Targeting both suPAR and dynamin may be beneficial across numerous types of renal disease.
About Walden Biosciences
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. Walden was launched in 2020 by ARCH Venture Partners and UCB Ventures and is headquartered in Cambridge, MA. For more information, please visit www.waldenbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005996/en/
Contacts
FTI Consulting
Robert Stanislaro
Robert.Stanislaro@fticonsulting.com
-OR-
Helen O’Gorman
Helen.O’Gorman@fticonsulting.com
Source: Walden Biosciences
View this news release online at:
http://www.businesswire.com/news/home/20210804005996/en
